📰 Olid News
Page 7 - Olid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Olid. Real-time updates on events, politics, business and more.
June 6, 2023
TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on... | June 6, 2023
June 6, 2023
Revenue growth target achieved: 16.3% Recurring EBITDA[1] €27.5m, EBITDA margin 11.5% €4.8m positive free cash flow Promising outlook for 2023/24 ABEO, a leading global supplier of sports and
June 6, 2023
According to the report, GitLab leads with a balance between solid platform capabilities and overall strategySAN FRANCISCO, June 06, 2023 -- All Remote - GitLab Inc., ​​the most... | June 6, 2023
June 5, 2023
British services firms reported the strongest input cost pressures in three months in May and a steep increase in prices charged against a backdrop of solid growth, adding further pressure on the... | June 5, 2023
June 5, 2023
Unveiling the Majesty of Carbon King: Alastair Gibson Presents a Solid Carbon Lion Skull
June 3, 2023
- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of... | June 3, 2023
June 2, 2023
New York, New York--(Newsfile Corp. - June 1, 2023) - JustAnEgg, a groundbreaking memecoin project, has officially launched in the crypto industry on May 19, 2023. Inspired by the unprecedented success
June 2, 2023
Nepal Prime Minister Pushpa Kamal Dahal aka Prachanda, on Friday, along with his cabinet visited Indores municipal corporations solid waste management plant and also saw Asias largest bio-CNG plant.
June 1, 2023
Huddlestock Fintech AS Q1 2023 Financial Report and Capital Markets Day Huddlestock delivers growth and is well prepared for the future after solid increase in revenue... | June 1, 2023
June 1, 2023
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelinPreclinical